Navigation Links
Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

Conference Call Scheduled for 5:00 p.m. ET Today

SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reported financial results for the fourth quarter and full year ended December 31, 2007. The company reported a net loss of $33.4 million ($0.43 per fully diluted share), for the fourth quarter of 2007, compared to a net loss of $30.3 million ($0.54 per fully diluted share) for the corresponding period in 2006. The net loss for the year ended December 31, 2007 was $99.3 million ($1.39 per fully diluted share), compared to a net loss of $82.9 million ($1.67 per fully diluted share) for the year ended December 31, 2006.

The increase in net loss in the fourth quarter of 2007 is attributed primarily to an increase in research and development costs. The increase in net loss for the 12 months ending December 31, 2007 is primarily due to a $9.8 million increase in research and development expenses as well as the net gain of $35.9 million realized in 2006 from the sale of the company's remaining shares of stock in its former subsidiary, Abgenix, Inc., which was partly offset in 2007 by $26.4 million from a favorable settlement with the Internal Revenue Service relating to the company's 2000 tax return.

The company's research and development costs were $28.5 million and $106.1 million in the fourth quarter and year ended December 31, 2007, respectively, compared to $24.6 million and $96.3 million for the comparable periods of 2006. The increase in research and development spending in the fourth quarter and the year ended December 31, 2007 is primarily due to expenses related to the ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, the company's lead product development program.

As of December 31, 2007, Cell Genesys had $147.3 million in cash, cash equivalents and short-term investments. Total 2007 spending was $105 million, which includes net cash used in operating activities of $89.7 million and net capital expenditures of $2.3 million offset by cash received in December of $12.0 million from the sale of the company's lentiviral gene delivery technology and $1.0 million from an agreement related to the company's gene activation technology. During 2007, Cell Genesys raised approximately $90 million in gross proceeds from equity financing.

"We believe we made substantial progress across our entire business during 2007 particularly with respect to our lead product program, GVAX immunotherapy for prostate cancer, which is now in advanced Phase 3 development," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "In the years ahead, we remain committed to doing everything we can to achieve our key product development goals and build shareholder value."

Recent Highlights

-- Announced in February 2008 results of an analysis examining the

potential association between immune responses to GVAX immunotherapy

for prostate cancer and increased patient survival in a Phase 2 trial

(G-0010) in patients with metastatic, hormone refractory prostate

cancer. An ongoing analysis of GVAX-induced antibody responses has

shown that at least two of the identified antibody responses are

associated with patient survival. These results were presented at the

American Society of Clinical Oncology's Genitourinary Cancer Symposium

held in mid-February.

-- Announced in January 2008 that the Independent Data Monitoring

Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical

trials of GVAX immunotherapy for prostate cancer, completed a

pre-planned interim analysis in the timeframe originally estimated and

has recommended that the study continue. As is customary to preserve

study blinding, the IDMC provided no information to the company other

than the recommendation to continue the trial. The company expects to

have enough events needed to trigger the final analysis of VITAL-1 in

the second half of 2009.

-- Announced in December 2007 the sale of Cell Genesys' lentiviral gene

delivery technology to GBP IP, LLC, an affiliate of GBP Capital, the

majority shareholder in privately held Lentigen Corporation, for $12.0


Presentations at Upcoming Investor Conferences

Members of the Cell Genesys management team plan to present at the following upcoming investor conferences:

-- Cowen & Co.'s 28th Annual Health Care Conference scheduled to occur

March 18 - 20 in Boston, Massachusetts;

-- 11th Annual Lehman Brothers Global Healthcare Conference scheduled to

occur March 18 in Miami, Florida; and

-- BioCentury's Future Leaders in the Biotech Industry Conference

scheduled to occur March 27 in New York City, New York.

Interested parties may access a live audio webcast of the presentation via the investor section of the Cell Genesys website, A replay of the presentation will be archived on the site for at least 72 hours following the presentation.

Conference Call and Webcast

Members of the Cell Genesys management team will host a conference call today, Thursday, February 28 at 5:00 p.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, Alternatively, investors may listen to a replay of the call by dialing (800) 475-6701 from locations in the United States and (320) 365-3844 from outside of the United States. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 910549.

About Cell Genesys

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at

Statements made in this press release about the company, other than statements of historical fact, including statements about the company's progress, results, analysis, and timing of our GVAX immunotherapy and oncolytic virus therapy clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ from the statements made, including but not limited to risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competing technologies and products, our ability to protect our intellectual property, litigation or other claims, the need for and reliance on collaborative business relationships and strategic partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.


Susan Ferris

Investor Relations





(unaudited, in thousands, except per share data)

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

Revenue $102 $90 $1,380 $1,364

Operating expenses:

Research and development 28,457 24,633 106,131 96,346

General and administrative 5,260 4,435 20,401 18,123

Restructuring charges - (25) - (82)

Total operating expenses 33,717 29,043 126,532 114,387

Loss from operations (33,615) (28,953) (125,152) (113,023)

Other income (expense):

Gain on sale of Abgenix,

Inc. common stock - - - 62,677

Gain (loss) on sale of

property and equipment (3) - 1,306 (2)

Interest and other income 2,919 2,088 9,021 7,497

Interest expense (2,570) (2,607) (10,331) (10,465)

Income (loss) before

income taxes (33,269) (29,472) (125,156) (53,316)

Income tax benefit (provision) (127) (778) 25,882 (29,613)

Net loss $(33,396) $(30,250) $(99,274) $(82,929)

Basic and diluted net loss

per common share $(0.43) $(0.54) $(1.39) $(1.67)

Weighted average shares

of common stock outstanding

- basic and diluted 78,297 55,522 71,255 49,728


(in thousands) December 31, December 31,

2007 2006

(unaudited) Note 1

Cash, cash equivalents and

short-term investments, including

restricted cash $147,306 $154,074

Prepaid expenses and other current assets 3,932 3,481

Property and equipment, net 119,011 129,643

Unamortized debt issuance costs and other assets 3,143 3,969

Total assets $273,392 $291,167

Other current liabilities $34,561 $15,904

Current portion of accrued income taxes 4 35,410

Other liabilities 3,451 2,851

Non-current portion of accrued income taxes 6,192 -

Non-current portion of capital lease obligation 46,635 48,475

Convertible senior notes 145,000 145,000

Stockholders' equity 37,549 43,527

Total liabilities and stockholders' equity $273,392 $291,167

Note 1. Derived from audited financial statements.

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results
2. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
3. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
4. Public Health Officials Warn About the Unrecognized Health Hazards of Smoking from a Hookah, Reports the Harvard Mental Health Letter
5. inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
6. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
7. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
8. Darwin Professional Underwriters, Inc. Reports Record Net Income of $10.9 Million for the Fourth Quarter
9. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
10. J.D. Power and Associates Reports: Riverview Medical Center Recognized for Providing an Emergency Department Experience
11. LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
(Date:11/28/2015)... ... ... EST until 11:59 p.m. EST, customers will be racing the clock to ... or more to free gifts with purchases, there will be a new sale available on ... skin care and cosmetic needs, customers will save on already discounted prices. , Top brands ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today ... Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ... users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: